Sumi A, Okuyama K, Kobayashi K, Ohtani W, Ohmura T, Yokoyama K
BIPHA Corporation, Hokkaido, Japan.
Bioseparation. 1999;8(1-5):195-200.
Two inter-related challenges must be overcome to develop a recombinant human serum albumin process. One is purity; the other is cost. Regarding cost, our goal is to produce recombinant human serum albumin at least as economically as plasma derived human serum albumin. To control production costs, maximum quantities of albumin must be produced from minimum volumes of cell culture, followed by high efficiency, high-yield purification methods. By introducing STREAMLINE technology, we have improved productivity by roughly 50% in terms of processing time and 45% in terms of yield. Furthermore, the life time of the gel and column are very long. After more than 1000 process cycles, performance remained unchanged.
要开发重组人血清白蛋白生产工艺，必须克服两个相互关联的挑战。一个是纯度；另一个是成本。在成本方面，我们的目标是以至少与血浆来源的人血清白蛋白一样经济的方式生产重组人血清白蛋白。为了控制生产成本，必须从最小体积的细胞培养物中生产出最大量的白蛋白，然后采用高效、高产的纯化方法。通过引入STREAMLINE技术，我们在处理时间方面提高了约50%的生产率，在产量方面提高了45%。此外，凝胶和柱子的使用寿命非常长。经过1000多个工艺循环后，性能仍保持不变。
